| Author | Treatment | N | Patient type | SD | PR | CR | ORR | TTP | CB | PFS | OS |
| Colleoni, 2002 | CP 50 mg qd po MTX 2.5 mg bd 2 days of 1 week po | 63 | Metastatic pretreated | - | 16% | 3% | 19.0% | - | 31.7% | - | - |
| Colleoni, 2006 | CP 50 mg qd po MTX 2.5 mg bd on 1st and 4th days po | 86 | Metastatic, pretreated and untreated | - | 17% | 3 | 20.9% | - | 41.5% | - | - |
| Colleoni, 2006 | CP 50 mg qd po MTX 2.5 mg bd on 1st and 4th days po Thalidomide 200 mg qd po | 85 | Metastatic, pretreated or untreated | - | 8% | 3 | 11.8% | - | 41.5% | - | - |
| Orlando, 2006 | MTX 2.5 mg bid on 1st and 2nd or 4th days po CP 50 mg qd po | 153 | Metastatic, pretreated or untreated | - | 16% | 5 | - | - | 15.7% (12 months ) | - | - |
| Orlando, 2006 | CP 50 mg qd po MTX 2.5 mg bid days 1, 4 q1w Trastuzumab 6 mg/kg q3w | 22 | Metastatic, pretreated, HER2 + | 46% | 18% | | - | - | - | 6 m | |
| Miscoria, 2012 | CP 50 mg qd po MTX 2.5 mg bid days 1, 4 q1w | 62 | Metastatic pretreated | | - | - | - | | - | 2.6m | 7.1 m |
| Gebbia, 2012 | CP 50 mg qd po | 22 | Metastatic pretreated hormone resistant | 9% | 3% | 0% | - | 3.8 m | ? | - | 12.8 m | vs. | Vs. | Vs. | Vs. | Vs. | | Vs. | | | Vs. | CP 50 mg qd po with MTX 2.5 mg bid 2 days per week | 39 | 12% | 8% | 0% | 4.2 m | 14 m | | | | | | |
| Wong, 2010 | CP 50 mg qd po MTX 2.5 mg bid po two days q1w Prednisone 5 mg qd | 41 | Metastatic, pretreated or untreated | 7% | 2% | 15% | 24% | 10 w | 24% | | 48 w |
| Garcia-Saenz, 2008 | CP 50 mg qd MTX 1 mg/kg iv q14d Bevacizumab 10 mg/kg iv q14d Trastuzumab (in HER2 +) | 22 | Metastatic, pretreated, HER2 +/- | 32% (24 w) | 32% | - | - | - | 63.6% | 7.5 m | 13.6 m |
| Mayer, 2012 | CP 50 mg qd MTX 2.5 mg qd 2 days per week Vandetanib 100 mg / 200 mg / 300 mg qd | 20 | Metastatic, pretreated or untreated | 15% (24 w) | 10% | - | - | - | - | - | - |
| Perroud, 2013 | CP 50 mg qd po Celecoxib 200 mg bid po | 155 | !! | 3% (24 w) | 1 patient | - | - | 14 w | 46.7% | 24 w (40%) | 12 m (46.7%) |
| Aurilio, 2012 | CP 50 mg qd po MTX 2.5 mg bd on 1st and 4th days per week po Fulvestrant 250 mg im q28d | 32 | Metastatic, pretreated, HR + | !! | !! | !! | !! | !! | 56% | - | - |
| Crivellari, 2013 | CP 50 mg qd po MTX 2.5 mg bd on 1st and 4th days per week po | 36 | Non-metastatic, >65 y, untreatable, HR- | - | Closed early | - | - | - | - | 42 w (81%) | - |
| Dellapasque, 2011 | CP 50 mg qd po Liposomal Doxorubicin 20mg/m2 | 29 | Non-metastatic, untreatable, preoperatively | 34.5% | 62.1% | - | - | - | - | - | - |
| Soriano, 2011 | CP 50 mg qd po MTX 2.5 mg bid 1E10-Alum | 21 | Metastatic, | 4% | - | - | - | 9.8 m | - | - | 12.9 m |
| Dellapasque, 2008 | CP 50 mg qd po Capecitabine 500 mg tid po Bevacizumab 10 mg/kg q2w | 46 | Metastatic | 17% | 46% | 2% | | 42 w | 68% | - | - |
| Licchetta, 2010 | CP 50 mg day 1-21 q28d po Megestrol acetate 80 mg bid po | 29 | Metastatic, pretreated, HR +/-, HER2 +/- | | | | 31% | 7.4 m | | | 13.4 m |
| Wang, 2012 | CP 65 mg /m2 iv days 1-14 q3w Capecitabine 1000 mg/m2 bid days 1-14 q3w | 68 | Metastatic, pretreated | - | - | - | 30.3% | 5.2 m | 53.0% | - | 16.9 m |
| Yoshimoto, 2012 | CP 33 mg/m2 bid days 1-14 q3w Capecitabine 828 mg/m2 bid days 1-14 q3w | 51 | Metastatic, HER2- ER-/ER+ | 13% | - | - | 44.4% | - | - | 10.7/13.2 | 1 y (86%) 2 y (71%) |
| Smith, 2000 | 5-FU 1 mg/m2 days 1-28 q35d po Eniluracil 10 mg/m2 days 1-28 q35d po | 29 | Metastatic | 24% (3 m) | 55% | | | | | | |
| Taguchi, 2010 | Capecitabine 825 mg/m2 bid days 1-21 q 28d | 33 | Metastatic, untreated recurrent | 24% (> 6 m) | - | - | 18% | - | - | 6.9 m | 24.8 m |
| Fedele, 2012 | Capecitabine 1500 mg qd | 58 | Metastatic, pretreated | | 2 (pretreated with Standard Capecitabine) | 7 (pretreated with Standard Capecitabine) | | 7 m | 62% | | 17 m |
| Watanabe, 2009 | UFT 300 mg tid | | T0, high risk, adjuvant | - | - | - | - | - | - | (RFS) 5 y (87.8 %) | 5 y (96.2 %) |
| Cazzaniga, 2014 | Capecitabine 500 mg tid Vinorelbine 20-30-40 mg/tot | 31 | Metastatic, pretreated, | - | - | - | - | - | 58.1% | - | - |
| Young, 2012 | Capecitabine 1250 mg/m2 qd Docetaxel 15mg/m2 Celecoxib 200 mg bid | 38 | Metastatic, pretreated | 8% (6 m) | 34% | - | - | 3.6 m | 42% | - | - |
| Schwartzberg, 2014 | Capecitabine 1500/2000 mg daily in divided doses Fulvestrant 500 mg day 1, 250 mg day 1, 15, 28 followed by 250 mg q28d | 41 | Metastatic, HR+, HER2- | - | - | - | - | 26.94 m | - | 14.98 m | 28.65 m |
| Otsuka, 2015 | Irinotecan 60 mg/m2 days 1, 8, 15 q4w TS-1 80 mg/m2 days 3-7, 10-14, 17-21 q4w | 34 | Metastatic, recurrent | 3% | 44% | - | - | | - | | |
| Alagizy, 2015 | Capecitabine 500 mg bid po | 41 | Operated, neoadjuvant FEC100+, +/- Postoperative RT, HR-, HER2- | - | - | - | - | - | - | -DFS- 42.4 m | 44.34 m (estimated) |
| Addeo, 2012 | Temozolomide with radiotherapy and following 4 w Temozolomide 75 mg/m2 days 1-21 q4w Vinorelbine 70 mg/m2 1,3,5 weekly for 3 w q4w, max 12 cycles | 36 | Untreated brain metastasis, | | 44% | 8% | 52% | - | - | 8 m | 11 m |
| Addeo, 2013 | Vinorelbine 70 mg/m2 1,3,5 weekly for 3 w q4w, max 12 cycles | 34 | Metastatic | - | 32% | 6% | - | - | - | 7.7 m | 15.9 m |
| Saloustros, 2011 | Vinorelbine 50 mg 3 times per week Bevacizumab 10 mg/kg 2 times per week q28d | 13 | Metastatic, pretreated | 46% | 8% | Closed early | - | - | - | - | - |
| De Iuliis, 2015 | Vinorelbine 30 mg q2d | 32 | Metastatic | | - | - | - | - | 50% | - | - |
| Bottini, 2006 | Letrozole 2.5 mg qd | 57 | HR+, | | - | - | 71.9% | | | - | - | Letrozole 2.5 mg qd and CP 50 mg qd 6 months | 57 | 87.7% |
| Manso, 2013 | NP-Liposomal Doxorubicin 30 mg iv 5-FU 500 mg iv Vincristine 0.25 mg iv CP 50 mg qd po Prednisone 20 mg | 38 | Metastatic, pretreated | 27% | - | - | | 281 d | | 8.4 m | 21 m |
| Masuda, 2014 | Paclitaxel 80 mg/m2 days 1. 8. 15, 4 cycles Cyclophosphamide 50 mg qd po 4 cycles Capecitabine 1200 mg/m2 qd 4 cycles 5-FU 500 mg/m2 q3w, 4 cycles Epirubicin 100 mg/m2 q3w, 4 cycles CP 500 mg/m2 q3w, 4 cycles | 33 | HR-, ER-, preoperative | - | 54.5% | - | - | - | 31 (93.9%) | - | - |
| Montagna, 2012 | Capecitabine 500 mg tid CP 50 mg qd Bevacizumab 15mg/kg q3w Erlotinib 100 mg qd | 24 | Metastatic, untreated, HR -, HER2- | 21% (9 w) | 58% | 4% | - | - | 75% | 43 w | - |
| Munzone, 2010 | P Liposomal-Doxorubicin | 45 | Metastatic, untreated, pretreated | 39% | 18% | - | - | - | 45% | - | - |
| Mutlu, 2015 | CP 50 mg qd po Etoposide 50 mg bid 2 days per week | - | Metastatic, pretreated | | | - | - | - | | 7.03 m | 32.5 m |
| Taguchi, 2013 | Capecitabine 828 mg/m2 bid po days 1-21 q28d Paclitaxel 80 mg/m2 days 1, 8, 15 q28d | 43 | Metastatic, pretreated | | | | 46.5% | | | 8.3 m | 22.9 m |
| Ambros, 2014 | Capecitabine 1000 m2 bid po days 1-14 q21d
| 86 | Metastatic, pretreated, HER2- | | | | 24.3% | 7 m | 55.8% | | 24.0 m |
| Neskovic, 1996 | Etoposide 50 mg/m2 po days 1-14 q 28d | 18 | Metastatic, untreated, pretreated | | 28% | 6% | | | | | |
| Yuan, 2015 | Etoposide 60 mg/m2 po days 1-10 q 21d | 75 | Metastatic, pretreated | 39% | 9% | | | | | 4.5 m | |
|
|